Axcella Health Inc (NASDAQ:AXLA) shares are soaring Tuesday after the company was granted a patent for long COVID fatigue treatment.
What To Know: The U.S. Patent and Trademark Office (USPTO) granted Axcella a patent covering methods of use of AXA1125 for treating a subject having post-acute sequelae of COVID-19 (long COVID), particularly fatigue.
AXA1125 is a novel composition of endogenous metabolic modulators designed to simultaneously support metabolic, inflammatory and fibrotic pathways associated with fatigue. The patent was issued Tuesday and has an expected expiration in 2042.
“We are pleased to have this additional designation as we pursue options to bring our investigational product forward for the benefit of the millions of people who continue to suffer from Long COVID Fatigue,” said Bill Hinshaw, president and CEO of Axcella.
See Also: EXCLUSIVE: Ocean Biomedical Announces New Patent For Fibrosis Candidate Catering To One Of Leading Death Causes In US
AXLA Price Action: Axcella shares were up 220.5% at 36 cents at the time of writing, according to Benzinga Pro.
Photo: StockSnap from Pixabay.
